Paper Details

  1. Home
  2. Paper Details

Patients treated with pimavanserin or quetiapine for Parkinson's disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries.

Author: DoshiDilesh, RajagopalanKrithika, RashidNazia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Pimavanserin (PIM) is an FDA-approved atypical antipsychotic for Parkinson’s Disease Psychosis (PDP), while quetiapine (QUE) is also used off-label. This study aimed to compare the real-world effects of PIM and QUE on health resource utilization (HCRU), providing insights into their relative benefits.
Paper Details　
Original Abstract of the Article :
Pimavanserin (PIM) is the only FDA approved atypical antipsychotic (AAP) for the treatment of Parkinson's Disease Psychosis (PDP) while other off-label AAPs like quetiapine (QUE) are also used. Real-world comparative effects of PIM and QUE on health resource utilization (HCRU) may provide insights a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/13696998.2023.2220597

データ提供：米国国立医学図書館（NLM）

Pimavanserin and Quetiapine: A Tale of Two Antipsychotics in Parkinson's Disease Psychosis

Parkinson's disease psychosis (PDP) is a challenging condition, often leaving patients feeling lost in a desert of confusion and disorientation. This research delves into the real-world utilization patterns of two antipsychotic medications, pimavanserin (PIM) and quetiapine (QUE), in treating PDP.

Comparing Health Resource Utilization Patterns

The study examines the comparative effects of PIM and QUE on health resource utilization (HCRU) among Medicare beneficiaries. The findings provide valuable real-world data on the impact of these medications on healthcare resource use.

Navigating the Treatment Landscape: A Guiding Compass

This research offers insights into the potential benefits and drawbacks of PIM and QUE in the treatment of PDP. By understanding their relative impact on HCRU, clinicians can make more informed decisions about medication choices and treatment strategies.

Dr.Camel's Conclusion

This research provides a valuable real-world perspective on the use of PIM and QUE in treating PDP. By shedding light on HCRU patterns, it offers clinicians a practical tool for navigating the complex treatment landscape of PDP. Understanding the differences in resource utilization can ultimately lead to more effective and cost-efficient care for patients.

Date :
  1. Date Completed 2023-06-15
  2. Date Revised 2023-06-15
Further Info :

Pubmed ID

37272069

DOI: Digital Object Identifier

10.1080/13696998.2023.2220597

Related Literature

Article Analysis
・Effects of pimavanserin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.